Nearly 17 million young Americans could be eligible for GLP-1RAs—a class of medications used to treat type 2 diabetes and obesity—including Ozempic and Wegovy.

This is based on estimations from Yale School of Medicine researchers who have assessed how many adolescents and young adults in the US are eligible for the drugs and how many can realistically access them.

Despite millions being eligible, one in five young adults who meet the criteria are uninsured and one-third denied having a routine place for healthcare.

The researchers describe this as "a barrier to identifying, treating, and preventing cardio-kidney-metabolic diseases".

The prevalence of type 2 diabetes and obesity continues to increase in youth across the country, hence the need for improved intervention.

"Assuming tha

See Full Page